Disease of orbital part of eye adnexa
MONDO:0004751Diseases of the bony orbit and contents except the eyeball.
Also known as: orbital disease
79 clinical trials for this condition and its sub-types, 2 tagged with Disease of orbital part of eye adnexa itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Disease of orbital part of eye adnexa
-
Endocrine exophthalmos 76 trials
2 sub-types
- Exophthalmic ophthalmoplegia 0 trials
- Thyrotoxic exophthalmos 0 trials
-
Acute orbital inflammation 0 trials · 3 incl. sub-types
4 sub-types
- Orbital cellulitis 3 trials
- Orbital osteomyelitis 0 trials
- Orbital periostitis 0 trials
- Orbital tenonitis 0 trials
-
Chronic orbital inflammation 0 trials
2 sub-types
- Orbital granuloma 0 trials
- Orbital pseudotumor 0 trials
-
Constant exophthalmos 0 trials
-
Enophthalmos 0 trials
-
Intermittent proptosis 0 trials
-
Lateral displacement of eye 0 trials
-
Orbital cyst 0 trials
-
Pulsating exophthalmos 0 trials
-
New drug aims to calm swollen eyes in thyroid disease patients
Disease control OngoingThis study tests an experimental drug called Lu AG22515 in 20 adults with moderate-to-severe thyroid eye disease, an autoimmune condition that causes eye swelling and bulging. The main goal is to see if the drug can reduce eye bulging over 24 weeks. Participants receive the drug …
Phase 1 • Sponsor: H. Lundbeck A/S • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for thyroid eye disease: phase 3 drug trial launches in china
Disease control OngoingThis study tests a new drug called ZL-1109 for people with moderate to severe thyroid eye disease, a condition that causes eye bulging and discomfort. About 99 Chinese adults will receive either the drug or a placebo to see if it safely reduces eye bulging by at least 2 millimete…
Phase 3 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New shot could ease bulging eyes in thyroid disease
Disease control OngoingThis Phase 3 trial tests an investigational drug called VRDN-003 for active thyroid eye disease, a condition that causes eye bulging, redness, and discomfort. The study involves 132 adults with moderate to severe symptoms. Participants receive either VRDN-003 or a placebo as a sh…
Phase 3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug could ease bulging eyes in thyroid disease
Disease control OngoingThis phase 3 trial tests an investigational drug called VRDN-003 in 204 people with chronic thyroid eye disease (TED). The drug is given as a shot under the skin and aims to reduce eye bulging and other symptoms. Participants are randomly assigned to receive either VRDN-003 or a …
Phase 3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New drug AMG 732 aims to reduce eye bulging in thyroid eye disease
Disease control OngoingThis study tests a new drug called AMG 732 for people with moderate-to-severe active thyroid eye disease, a condition that causes eye bulging and discomfort. The trial has two parts: Part A checks safety in healthy volunteers, and Part B tests how well the drug works in patients.…
Phase 1/2 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New shot could ease bulging eyes from thyroid disease
Disease control OngoingThis phase 3 trial tests an injectable drug called teprotumumab for people with moderate-to-severe active thyroid eye disease, a condition that causes eye bulging and discomfort. About 89 adults will receive either the drug or a placebo injection to see if it reduces eye bulging …
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New shot could tame thyroid eye disease
Disease control OngoingThis phase 3 trial tests an investigational drug called VRDN-003, given as an injection under the skin, for people with thyroid eye disease. The study involves 320 participants and aims to check the drug's safety and tolerability. Researchers will also measure if it reduces eye b…
Phase 3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New injection every 8 weeks shows promise for thyroid eye disease
Disease control OngoingThis study tests a drug called TOUR006 in 79 people with active thyroid eye disease, a condition that causes eye bulging and inflammation. Participants receive either a low dose, high dose, or placebo injection every 8 weeks. The main goal is to see if the drug can reduce eye bul…
Phase 2 • Sponsor: Tourmaline Bio, Inc., a Novartis Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Light mask may soothe dry eyes in Graves' patients
Symptom relief By invitation onlyThis study tests a low-level light therapy mask for dry eye disease in people with Graves' eye disease who haven't improved with standard treatments. Thirty adults will receive either the real light therapy or a sham device. The goal is to see if the treatment improves tear film …
Sponsor: Grigore T. Popa University of Medicine and Pharmacy • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Tear test could spot eye disease risk in thyroid patients
Knowledge-focused OngoingThis research study aims to create a simple, non-invasive test using tears and blood to predict which patients with hyperthyroidism are at risk of developing Graves' Orbitopathy (eye disease). Researchers will analyze samples from 90 participants, including healthy controls and t…
Sponsor: University Hospital, Ghent • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New drug NTB003 enters first human safety tests
Knowledge-focused By invitation onlyThis Phase 1 trial is testing a new drug called NTB003 in 40 healthy adults to see if it is safe and how the body processes it. Participants will receive either NTB003 or a placebo in increasing doses. The study is an early step toward possibly treating thyroid eye disease, but i…
Phase 1 • Sponsor: Nanjing Chia-tai Tianqing Pharmaceutical • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:57 UTC